Get started

MJNA

MJNA is going to go through the roof IMO 😳OMG, this is finally happening folks. The house passed the marijuana banking bill, and the senate is now dem controlled. The act passed with 76% approval in the House. If the Senate can get the same level of support, this bill will pass whether the president wants it to or not. Who knows, the President may support this bill. I've been waiting a decade for this news. 😵 Tomorrow is the time to get on the boat. 😳
OTC:MJNALong
by Shouldabeenabillionaire
3
2degreez - MJNA BULLISH - Proceed with Extreme CautionI do not normally do penny stocks but I might post 1 from time to time. HIGHLY DANGEROUS - EXTREMELY CAUTIOUS - NOT FINANCIAL ADVICE I played MJNA a few times over the the past several years and was lucky enough to rode it up to .25 back in 2013. Educational chart post only. The Content is for informational and educational purposes only. This is not in any way, shape or form financial or trading advice. Good luck, happy trading and stay chill, 2degreez
OTC:MJNALong
by UnknownUnicorn7216011
1
MJNA Target 0.50 - 1.00This stock is pretty much looked at as the otc ETF for the marijuana sector. Target based on the sector. The other targets I have mentioned are based on company financials and fundamentals Business Description Medical Marijuana Inc. (OTC Pink Sheets; MJNA) is the first publicly held company vested in the cannabis and industrial hemp space in America. Through its subsidiaries and investment holdings the Company focuses on the development, sale and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol ("CBD") and other products containing CBD-rich hemp oil ("Legal Hemp"). Company products are formulated for the pharmaceutical, nutraceutical and cosmeceutical industries, including dietary supplements, prescription-based hemp oil for sale in countries that have legalized our hemp oil for the treatment of various illnesses and conditions (such as Brazil and Mexico) and skin care products. The Company is not in the business of selling or dispensing either recreational or medical marijuana, directly or indirectly, so long as marijuana remains a federally controlled substance, however, we are poised and consider ourselves well-positioned for eventual cannabis legalization (the Company's products contain only those substances that are derived from the part of the cannabis plant that is excluded from the definition of marijuana under the Controlled Substances Act and are both federally legal and outside of the purview of the Drug Enforcement Administration). Medical Marijuana, Inc. and Subsidiaries HempMeds® Mexico, HempMeds® Brazil and Kannaway® Announce 2017 as the Largest Revenue Year in Company History PR Newswire SAN DIEGO, Jan. 8, 2018 SAN DIEGO, Jan. 8, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Company and its subsidiaries HempMeds® Mexico, HempMeds® Brazil and Kannaway® generated the largest-ever (unaudited) revenue year in its history in 2017, as well as reached major milestones in its business operations. In 2017, Medical Marijuana, Inc. had a number of significant accomplishments, including: Experienced year over year revenue growth of more than 300% compared to 2016 Medical Marijuana, Inc. CEO Dr. Stuart Titus spoke at several national and international cannabis conferences including A4M Mexico, the California Cannabis Business Expo, World Medical Cannabis Conference & Expo, ExpoWeed, the International Fair of Medical Cannabis and the Marijuana Business Conference & Expo Announced the promotion of Vice President of Operations, who also serves as Kannaway CEO, Blake N. Schroeder, Esq., to Chief Operating Officer Appointed Alex Grapov as new International Vice President, Jim Gibson as new Vice President of Operations and Stephen Jones as Chief Marketing Officer Medical Marijuana, Inc. subsidiary Kannaway® was the first direct sales company to offer phyto-cannabinoid botanical products to consumers. A family-oriented company, Kannaway® encourages its brand ambassadors to create their own successful distribution businesses that will positively benefit the wellbeing of the people around them. In 2017, Kannaway® had a number of significant accomplishments including: Launched new products including a Hempy's® line of clothing products, Kannaway® Energy Chews, Kannaway® Essential Oils, updated HempVAP® Terpene-infused Vape, Kannaway® SuperGreens and Kannaway® Pure Gold Announced international expansion with the establishment of Kannaway® Europe Experienced year over year revenue growth of more than 500% compared to 2016 Achieved the largest sales year in its history. HempMeds® Mexico is Medical Marijuana, Inc.'s distribution branch in the country, focusing on providing non-psychoactive cannabidiol (CBD) products to the people of Mexico. HempMeds® Mexico was the first company to have a medical cannabis product approved for import into Mexi
OTC:MJNALong
by StockPicksNYC98
$EHVVF Continues to Move in Anticipation of Canadian MJ+ Updates"We have executed and expanded the commitments we have made to our mental health (Multi Health Systems) and therapeutic partners (MedReleaf TSX: LEAF), entered new partnerships to expand our market verticals to include the pharmaceutical industry (Aequus TSX-V: AQS). Meanwhile, we have been preparing for our next set of trials of our new video games for assessment & remediation of ADD/ADHD developed in collaboration with The Hospital for Sick Children in Toronto." "Pharmaceutical Trials In July 2017, we signed a Letter of Intent with Aequus Pharmaceuticals for Ehave solutions to be used for the assessment, diagnostic, therapeutic and outcome management for use in informal and formal clinical trials. The intent is for the Ehave Platform and patient reported outcomes application to be used by clinicians and patients of Aequus trials, with content to be customized based on the specific needs of the trial protocols for both traditional and Cannabis CBD-based treatments. This is a significant milestone for Ehave – opening up a new market vertical to demonstrate the value of the Ehave informatics platform in clinical trails. We believe that we can bring the cost of trials down substantially and be the first Digital CRO in the market." "We have a management team that has built, grown and operated high value organizations before, including my experience in building a $10M cancer informatics solution for Princess Margaret Cancer Center, being an executive at Mount Sinai Hospital in Toronto that had a $330M operating budget, the $40M exit of Casero to Radial Point where I was a founding employee, and being an early employee of Solect Technology Group which sold to Amdocs for $1.2B. In addition, we have a world class Board of Directors with health technology, pharmaceutical and insurance expertise." 13g Filed A/H's Nov, 9th 2017 Name of Person Filing EISENBERG FAMILY FOUNDATION, INC. Income of over $100 Million. www.taxexemptworld.com ih.advfn.com
OTC:EHVVFLong
by StockGuild
Finally!! FDA Number for Premature Ejaculation Drug IS IN! LOS ANGELES, CA--(Marketwired - June 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code (NDC) 69006-010-00 from the Food and Drug Administration (FDA) for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation. The company's FDA Registered Prolayed combines Lidocaine as the active ingredient with ViaDerma's proprietary transdermal delivery system. The new "OTC Drug" is now ready for sale. The Company's recent testing has proved to be successful. The market for Premature Ejaculation (PE) is estimated to be $1.3 billion in 2017. The Company's topical solution does not have to be ingested and processed through the body's internal organs. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues in the near future. This is another product in the "Go to Market Strategies" pipeline. The Company already has located a suitable manufacturer and seeks distributors. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several new products. Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company. Now, men can purchase the spray themselves directly from an online pharmacy. In other reported testing, the product works on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment market has been estimated to be approximately $1.3 Billion dollars for 2017, up from about $684 million dollars in 2010 based on the U.S. and European approval of several new products. Trends, Technologies & Opportunities Report for 2016-2020 with key vendors being Pfizer, Emcure, Eli Lilly. In Technavio's report, Global Premature Ejaculation Treatment Market for the 4-year period states that the analysts forecast for the global PE treatment market to grow at a CAGR of 9.65% during that period. Company Update The production of the Company's topical antibiotic is still on track and the Company is finalizing purchase orders for the product which should be shipped to distributors within the next few weeks. Also, the Company has had new inquiries from distributors in South Korea, and a meeting is scheduled in the first week of July to finalize a sales agreement. The lawsuit filed against the Company has been answered and the Company's legal counsel Austin Legal Group, from San Diego, has filed a motion to dismiss the plaintiffs' claims in Federal Court.
OTC:VDRMLong
by Cryptocol
MM's shaking out weak handsNothing new here, seen this time and time again with VDRM. Company gets good news and stock "tanks". Always rebounds and always comes back stronger. Chart is still strong looking and once we get serious volume rolling in again I think we skyrocket straight to a nickel. FDA approval could push this even further to dime land. We will see. Longs must be patient, good things will come, do not fall for the tricks and get ruined by dirty tactics. Long and strong. Millionaires will be made!
OTC:VDRMLong
by Cryptocol
$MCOA Making moves Ready for 3rd Major leg up on Weekly Chart.$MCOA QUICK TAKE-AWAYS AND WHY I'M EXCITED! 1. Less than two weeks ago announced an investment of $250,000 for 15% of MoneyTrac Technology Inc. 2. Currently has Investments/Ownership/Joint Ventures with the following companies: hostedimages-cdn.aweber-static.com 3. $MCOA has its hands in real-estate for growing, brand marketing, hemp product ventures, and more. An area where several of upper management has succeeded before. 4. In April they formed a JV with Bougainville in which $MCOA will invest $1,000,000 into a newly formed entity for the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington.Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility, which will accommodate a Tier-3 production and processing I-502 tenant. 5. They completed a PCOAB Audit in late March to get ever closer in their move to the OTCQB Exchange. 6. In March $MCOA continued their national expansion with a production permit in Adelanto, California. 7. They launched their HempSMART website and HempSMART Brain product also this year: www.hempsmart.com 8. Audited Fins for the last two years completed 9. It's up 100,000% since 2015 and STILL going up. This might be the 3rd major leg forming now on the weekly chart. 9. The chart, need I say more? Lol All in all I am liking what I'm seeing here. Go $MCOA!
OTC:MCOALong
by StockGuild
$OWCP Bullish Pennant Formation with Upcoming MJ Catalysts News ANNUAL REPORT CLARIFICATION FOR SHAREHOLDERS: 1) Page 5: Don't get confused by the OWCP already done Psoriasis study (where efficacy results are imminent) and next deeper and extended studies planned from April: "On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Company determined to extend the size and scope of the Study for the purpose, among other things, of checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, the Registrant expects to compete the Study during the 2 nd or 3 rd quarters of 2017." The study already done is confirmed in page 36: "We have been conducting a study on the efficacy of the cannabinoid-based topical cream for the treatment of skin conditions generally and psoriasis specifically, which commenced in November, 2016 " While the extended study to start in April 2017 according to previous 8K is the safety phase and identification of biological markers useful to identify potential other application of the cream (Skin Cancer imo): "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments" 2) Page 5-6: Multiple Myeloma Amazing News for Shareholders is here: "Dr. Leiba led our in vitro studies on the effect of a formulation comprised of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cells studied outside their normal biological context. The results indicated a 100% mortality rate of myeloma cells in 80% of the cultured cells within a 24 to 48-hour period, and highlight the potential abilities of cannabis oil extract to fight multiple myeloma cancer cells. We believe that the results of this study indicate a potential to develop a more effective treatment for multiple myeloma than standard therapies." "Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study" "Intend to commence a clinical study in the third quarter of 2017" 3) Notes on competition page 7: For Psoriasis they aim to attack Big Pharma market and they are well aware of current products and thier limitation: "The current common treatments for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs such as Cyclosporine A (by Novartis), methotrexate or MTX and biological drugs such as Enbrel (by Amgen), Amevive (by Biogen but whose patent expired in 2013) and Ustakinumabn (by Janssen Immunology)." This is excelent Marketing strategic approach; 4) Page 8: Provisional Patents are listed in report, can be downloaded through reference number and are real! They are extremely well written in a professional way and full of interesting claims: when needed (close to deadline) they will pay the service fees and transform them in Official US Permanent Patent; Why to do it before if the provisional is free of charge? Smart approach; 5) Page 12: CERTIFICATION and FDA approval all diligently work has been done according to standard: " Israel’s Ministry of Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA, making it comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements, thereby enabling medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited fashion. Many members of Israel’s medical community have earned international prestige in their chosen fields of expertise and routinely collaborate, teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with the United States
OTC:OWCPLong
by StockGuild
$ATTBF History Repeats Itself 2014 Run from .0125 to $2.85Remember the first MJ Rush in 2014? $ATTBF one of the few stocks HQ'ed in Canada but traded in America with its second symbol went from .0125 to $2.85 on Colorado recreationally legalizing MJ back in 2012 and the law was implemented that year and a few others legalized it recreationally and medically as well. Well now that beautiful rush has come full circle once again. Those states that legalized it that year implemented it last year and those profits will be on balance sheets this year, in addition Canada is going to approve recreationally Marijuana legally across their entire country on April 20th. With $ATTBF HQ'ed in Canada this is the green gold everyone will be waiting for. MJ stocks will shoot up, but MJ stocks from Canada will more than likely shoot even higher. $ATTBF has the best of both worlds, Bio and Medical Marijuana and other MJ products, a beautiful marriage of everything we love in both worlds. The chart and technical are primed for a beautiful run upwards. I would not say its outrageous to suggest a PPS target of $3.00 or more this time around. As can be seen, this stock has shown true strength and movement when it wants to.
OTC:ATTBFLong
by StockGuild